Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease

Key facts

Study ID

NCT02970019

Run by

Sun Pharma Advanced Research Company Limited

People needed

60

Starts

2017-03-30

Expected to finish

2019-05-28

Last updated by the study team

2020-03-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to give written, and dated, informed consent (or legally acceptable representative/impartial witness when applicable) and is available for the entire study
• Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions (in the Investigator's opinion), and be accessible for follow-up
• Male or female aged 18 to 65 years (both inclusive)
• Diagnosed with Parkinson's disease

You may not qualify if…

• Clinical diagnosis of genetic form of Parkinson's disease, or drug-induced parkinsonism
• Diagnosis of Parkinson's disease Dementia (probable, possible)
• Presence of severe dyskinesias
• History of brain surgery for Parkinson's disease

Where it is running

• SPARC Site 03 — Long Beach, California, United States
• SPARC Site 05 — Panorama City, California, United States
• SPARC Site 01 — DeLand, Florida, United States
• SPARC Site 02 — Orlando, Florida, United States
• SPARC Site 04 — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.